EU Clears 700-mg Every-6-Week Cemiplimab Dosing Across All Six Indications
The European Commission approved 700-mg every-6-week cemiplimab maintenance across all six indications, with 15-minute infusions permitted. An FDA decision is expected in March 2027.
